Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Respiratory SystemDRG 182-respiratory-neoplasms-without-cc-mcc
    Ask Trek AI about this page

    Respiratory Neoplasms without CC/MCC: Inpatient Reimbursement Overview

    DRG 182 encompasses hospital admissions for primary malignant neoplasms of the respiratory system without Complication or Comorbidity or Major Complication or Comorbidity, covering routine surgical or medical care for lung cancer when no additional coded complications exist. This grouping matters for inpatient reimbursement because it sets the prospective payment level under Medicare and hinges on accurate coding of comorbidities to determine appropriate payment tiering.

    Customize your policy alerts

    Sign up for drg 182 policy alerts

    Get alerted when payer policies referencing 182 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 182 Overview

    DRG 182 covers inpatient admissions for primary malignant respiratory neoplasms without documented Complication or Comorbidity and without Major Complication or Comorbidity. This category typically includes straightforward hospital stays for diagnostic workup, limited surgical resection, or medical management of primary lung cancer when no additional coded complications are present. It matters for Medicare payment because classification into this Diagnosis-Related Group determines the base prospective payment and influences resource allocation for hospitals. Correct coding of comorbidities and complications affects payment tiering between DRG 182 and higher-paying groups.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative and neoadjuvant therapy trials evaluating timing and sequencing of chemotherapy and/or radiotherapy for patients with resectable respiratory neoplasms. These studies enroll inpatients who are planned for surgical resection or are receiving inpatient perioperative care, comparing outcomes such as tumor downstaging, rates of complete (R0) resection, postoperative complications, and length of stay. Results are directly relevant to providers and payers because optimizing preoperative treatment can reduce operative morbidity, readmissions, and overall inpatient resource utilization tied to this DRG.
    • Comparative effectiveness studies of inpatient management strategies for complications of respiratory neoplasms, such as hemoptysis control, malignant pleural effusion management, or acute airway obstruction. These studies compare interventions (for example, endobronchial procedures versus chest tube/drain strategies, or different protocols for transfusion and hemostasis) in hospitalized patients to measure short-term outcomes like need for escalation of care, ICU transfer, procedural success, and hospitalization costs. Payers and hospitals benefit from evidence about which approaches shorten length of stay, lower complication and readmission rates, and improve cost-effectiveness for patients classified in this DRG.
    • Post-discharge and survivorship outcome studies assessing functional recovery, symptom burden, and healthcare utilization after inpatient treatment for respiratory neoplasms without CC/MCC. Cohorts follow patients discharged after surgery or inpatient procedures to evaluate readmission drivers, outpatient therapy adherence, palliative needs, and quality-of-life trajectories over months to years. This research informs discharge planning, transitional care interventions, and reimbursement models by identifying targets to reduce avoidable readmissions and downstream costs for this patient population.

    Related Codes

    163-MAJOR-CHEST-PROCEDURES-WITH-MCC

    Major Chest Procedures with MCC: Inpatient Reimbursement Overview

    164-MAJOR-CHEST-PROCEDURES-WITH-CC

    Major Chest Procedures with CC: Inpatient Reimbursement Overview

    165-MAJOR-CHEST-PROCEDURES-WITHOUT-CC-MCC

    Major Chest Procedures without CC/MCC: Inpatient Reimbursement Overview

    166-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-MCC

    Other Respiratory System O.R. Procedures with MCC: Inpatient Reimbursement Overview

    167-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-CC

    Other Respiratory System O.R. Procedures with CC: Inpatient Reimbursement Overview

    168-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITHOUT-CC-MCC

    Other Respiratory System O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    173-ULTRASOUND-ACCELERATED-AND-OTHER-THROMBOLYSIS-WITH-PRINCIPAL-DIAGNOSIS-PULMONARY-EMBOLISM

    Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism: Inpatient Reimbursement Overview

    175-PULMONARY-EMBOLISM-WITH-MCC-OR-ACUTE-COR-PULMONALE

    Pulmonary Embolism with MCC or Acute Cor Pulmonale: Inpatient Reimbursement Overview

    176-PULMONARY-EMBOLISM-WITHOUT-MCC

    Pulmonary Embolism without MCC: Inpatient Reimbursement Overview

    177-RESPIRATORY-INFECTIONS-AND-INFLAMMATIONS-WITH-MCC

    Respiratory Infections and Inflammations with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 40

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.